This week's artwork was donated by Lauren , a pediatric cancer patient who received treatment at The Children's Hospital of Philadelphia .
Tamoxifen is advantageous in treating all stages of breast cancer.
However, studies have suggested that incidence and severity of endometrial cancer increase in women treated with tamoxifen. Average time on study is 8 years for randomly assigned patients and 5 years for registered patients. The incidence rates of liver, gastrointestinal, urinary tract, and nonuterine genital tumors were not increased by tamoxifen treatment. Twenty-five endometrial cancers were originally reported, one of which was reclassified after subsequent review. Two cases occurred in the placebo group in patients whose medical status subsequent to random assignment had required tamoxifen treatment.